The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Bexsero meningococcal group B Vaccine (rDNA, component, adsorbed) | GSK Vaccines S.r.l. | Meningitis, Meningococcal | 🇪🇺 EU 2013-01-13 | Order → |
| Krystexxa pegloticase | Crealta Pharmaceuticals Ireland Limited | Gout | 🇪🇺 EU 2013-01-08 | Order → |
| Imatinib Teva imatinib Generic | Teva B.V. | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Hypereosinophilic | 🇪🇺 EU 2013-01-07 | Order → |
| Betmiga mirabegron | Astellas Pharma Europe B.V. | Urinary Bladder, Overactive | 🇪🇺 EU 2012-12-20 | Order → |
| NexoBrid concentrate of proteolytic enzymes enriched in bromelain | MediWound Germany GmbH | Debridement | 🇪🇺 EU 2012-12-18 | Order → |
| Constella linaclotide | AbbVie Deutschland GmbH & Co. KG | Irritable Bowel Syndrome | 🇪🇺 EU 2012-11-26 | Order → |
| Memantine Merz memantine hydrochloride | Merz Pharmaceuticals GmbH | Alzheimer Disease | 🇪🇺 EU 2012-11-22 | Order → |
| Eylea aflibercept | Bayer AG | Wet Macular Degeneration; Macular Edema; Diabetes Complications; Retinal Vein Occlusion; Choroidal Neovascularization | 🇪🇺 EU 2012-11-21 | Order → |
| Capecitabine Medac capecitabine Generic | medac Gesellschaft für klinische Spezialpräparate mbH | Colorectal Neoplasms | 🇪🇺 EU 2012-11-19 | Order → |
| Zoledronic Acid Hospira zoledronic acid Generic | Pfizer Europe MA EEIG | Hypercalcemia | 🇪🇺 EU 2012-11-19 | Order → |
| Ibandronic acid Accord ibandronic acid Generic | Accord Healthcare S.L.U. | Wounds and Injuries; Breast Diseases; Neoplastic Processes; Calcium Metabolism Disorders; Water-Electrolyte Imbalance | 🇪🇺 EU 2012-11-18 | Order → |
| Picato ingenol mebutate Additional monitoring | LEO Laboratories Ltd. | Keratosis, Actinic | 🇪🇺 EU 2012-11-15 | Order → |
| Forxiga dapagliflozin | AstraZeneca AB | Diabetes Mellitus, Type 2; Heart Failure, Systolic; Heart Failure; Renal Insufficiency, Chronic | 🇪🇺 EU 2012-11-11 | Order → |
| Adcetris brentuximab vedotin | Takeda Pharma A/S | Lymphoma, Non-Hodgkin; Hodgkin Disease | 🇪🇺 EU 2012-10-25 | Order → |
| Glybera alipogene tiparvovec ATMPExceptional circumstancesAdditional monitoring | uniQure biopharma B.V. | Hyperlipoproteinemia Type I | 🇪🇺 EU 2012-10-25 | Order → |
| Xalkori crizotinib | Pfizer Europe MA EEIG | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2012-10-23 | Order → |
| Enurev Breezhaler glycopyrronium bromide | Novartis Europharm Ltd | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2012-09-28 | Order → |
| Seebri Breezhaler glycopyrronium bromide | Novartis Europharm Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2012-09-28 | Order → |
| Tovanor Breezhaler glycopyrronium bromide | Novartis Europharm Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2012-09-28 | Order → |
| Dacogen decitabine | Leukemia, Myeloid | 🇪🇺 EU 2012-09-20 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.